Analysis of an ankyrin-like region in Epstein Barr Virus encoded (EBV) BZLF-1 (ZEBRA) protein: Implications for interactions with NF-κB and p53

Virology Journal

Volumn 8, Issue , 2011, Pages

  Dreyfus, David H ^a   Liu, Yang ^b   Ghoda, Lucy Y ^c   Chang, Joseph T ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c Keren Pharmaceuticals   (United States)

Author keywords

ankyrin; ASPP1; ASPP2; epi genomics; iASPP; NF B; oncogenes; p53; phylogeny; ping pong evolution; transcription; viral carcinogenesis; viral conditioning

Indexed keywords

ANKYRIN; I KAPPA B; IMMEDIATE EARLY PROTEIN BZLF1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR FOSB; TRANSCRIPTION FACTOR JUNB; UNCLASSIFIED DRUG; ZEBRA ANKYRIN LIKER REGION; BZLF1 PROTEIN, HERPESVIRUS 4, HUMAN; TRANSACTIVATOR PROTEIN;

AMINO ACID SEQUENCE; ANALYSIS; ARTICLE; COMPUTER MODEL; EPSTEIN BARR VIRUS; NONHUMAN; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; EPSTEIN BARR VIRUS INFECTION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; PHYLOGENY; PROMOTER REGION; PROTEIN TERTIARY STRUCTURE; SEQUENCE ALIGNMENT; VIROLOGY;

CACTACEAE; DNA VIRUSES; EQUUS SUBG. HIPPOTIGRIS; HUMAN HERPESVIRUS 4; INVERTEBRATA;

AMINO ACID SEQUENCE; ANKYRINS; BINDING SITES; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NF-KAPPA B; PHYLOGENY; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ALIGNMENT; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80052587022     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-422     Document Type: Article

References (57)

1. EBV-associated neoplasms: alternative pathogenetic pathways. Niller HH, Salamon D, Ilg K, Koroknai A, Banati F, Schwarzmann F, Wolf H, Minarovits J, Med Hypotheses 2004 62 387 391 10.1016/j.mehy.2003.11.001 14975509 (Pubitemid 38388901)
2. A 30 kb region of the Epstein-Barr virus genome is colinear with the rearranged human immunoglobulin gene loci: implications for a "ping-pong evolution" model for persisting viruses and their hosts. A review. Niller HH, Salamon D, Rahmann S, Ilg K, Koroknai A, Banati F, Schwarzmann F, Wolf H, Minarovits J, Acta Microbiol Immunol Hung 2004 51 469 484 10.1556/AMicr.51.2004. 4.7 15704335 (Pubitemid 40064115)
3. Epstein-Barr virus infection of T cells: implications for altered T-lymphocyte activation, repertoire development and autoimmunity. Dreyfus DH, Kelleher CA, Jones JF, Gelfand EW, Immunol Rev 1996 152 89 110 10.1111/j.1600-065X.1996.tb00912.x 8930669 (Pubitemid 26362754)
4. Immune system: success owed to a virus? Dreyfus DH, Science 2009 325 392 393 19628840
5. Paleo-immunology: evidence consistent with insertion of a primordial herpes virus-like element in the origins of acquired immunity. Dreyfus DH, PLoS One 2009 4 5778 10.1371/journal.pone.0005778 19492059
6. Modulation of p53 activity by IkappaBalpha: evidence suggesting a common phylogeny between NF-kappaB and p53 transcription factors. Dreyfus DH, Nagasawa M, Gelfand EW, Ghoda LY, BMC Immunol 2005 6 12 10.1186/1471-2172-6-12 15969767 (Pubitemid 41418112)
7. Lytic cycle switches of oncogenic human gammaherpesviruses. Miller G, El-Guindy A, Countryman J, Ye J, Gradoville L, Adv Cancer Res 2007 97 81 109 17419942 (Pubitemid 46528986)
8. Structural basis of lytic cycle activation by the Epstein-Barr virus ZEBRA protein. Petosa C, Morand P, Baudin F, Moulin M, Artero JB, Muller CW, Mol Cell 2006 21 565 572 10.1016/j.molcel.2006.01.006 16483937 (Pubitemid 43228011)
9. The bZIP transactivator of Epstein-Barr virus, BZLF1, functionally and physically interacts with the p65 subunit of NF-kappa B. Gutsch DE, Holley-Guthrie EA, Zhang Q, Stein B, Blanar MA, Baldwin AS, Kenney SC, Mol Cell Biol 1994 14 1939 1948 8114725 (Pubitemid 24074589)
10. BZLF1, an Epstein-Barr virus immediate-early protein, induces p65 nuclear translocation while inhibiting p65 transcriptional function. Morrison TE, Kenney SC, Virology 2004 328 219 232 10.1016/j.virol.2004.07.020 15464842 (Pubitemid 39349471)
11. Atypical bZIP domain of viral transcription factor contributes to stability of dimer formation and transcriptional function. Schelcher C, Al Mehairi S, Verrall E, Hope Q, Flower K, Bromley B, Woolfson DN, West MJ, Sinclair AJ, J Virol 2007 81 7149 7155 10.1128/JVI.00215-07 17459922 (Pubitemid 46986650)
12. Mutation of a single amino acid residue in the basic region of the Epstein-Barr virus (EBV) lytic cycle switch protein Zta (BZLF1) prevents reactivation of EBV from latency. Schelcher C, Valencia S, Delecluse HJ, Hicks M, Sinclair AJ, J Virol 2005 79 13822 13828 10.1128/JVI.79.21.13822-13828.2005 16227304 (Pubitemid 41508196)
13. Interaction of Epstein-Barr virus BZLF1 C-terminal tail structure and core zipper is required for DNA replication but not for promoter transactivation. McDonald CM, Petosa C, Farrell PJ, J Virol 2009 83 3397 3401 10.1128/JVI.02500-08 19144704
14. A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. Ma SD, Hegde S, Young KH, Sullivan R, Rajesh D, Zhou Y, Jankowska-Gan E, Burlingham WJ, Sun X, Gulley ML, et al. J Virol 2011 85 165 177 10.1128/JVI.01512-10 20980506
15. Inhibition of IFN-gamma signaling by an Epstein-Barr virus immediate-early protein. Morrison TE, Mauser A, Wong A, Ting JP, Kenney SC, Immunity 2001 15 787 799 10.1016/S1074-7613(01)00226-6 11728340 (Pubitemid 34008506)
16. Epstein-Barr virus immediate-early protein BZLF1 inhibits tumor necrosis factor alpha-induced signaling and apoptosis by downregulating tumor necrosis factor receptor 1. Morrison TE, Mauser A, Klingelhutz A, Kenney SC, J Virol 2004 78 544 549 10.1128/JVI.78.1.544-549.2004 14671137 (Pubitemid 37549767)
17. The crystal structure of the IkappaBalpha/NF-kappaB complex reveals mechanisms of NF-kappaB inactivation. Huxford T, Huang DB, Malek S, Ghosh G, Cell 1998 95 759 770 10.1016/S0092-8674(00)81699-2 9865694 (Pubitemid 29014456)
18. Structure of an IkappaBalpha/NF-kappaB complex. Jacobs MD, Harrison SC, Cell 1998 95 749 758 10.1016/S0092-8674(00)81698-0 9865693 (Pubitemid 29014455)
19. Antisense to the epstein-barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and bcl-2 expression and promotes apoptosis in EBV-immortalized B cells. Kenney JL, Guinness ME, Curiel T, Lacy J, Blood 1998 92 1721 1727 9716601 (Pubitemid 28406877)
20. Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors. Feng WH, Westphal E, Mauser A, Raab-Traub N, Gulley ML, Busson P, Kenney SC, J Virol 2002 76 10951 10959 10.1128/JVI.76.21.10951-10959.2002 12368338 (Pubitemid 35176212)
21. Inactivation of NF-kappaB by EBV BZLF-1-encoded ZEBRA protein in human T cells. Dreyfus DH, Nagasawa M, Pratt JC, Kelleher CA, Gelfand EW, J Immunol 1999 163 6261 6268 10570319
22. Epstein-Barr virus replicative gene transcription during de novo infection of human thymocytes: simultaneous early expression of BZLF-1 and its repressor RAZ. Kelleher CA, Paterson RK, Dreyfus DH, Streib JE, Xu JW, Takase K, Jones JF, Gelfand EW, Virology 1995 208 685 695 10.1006/viro.1995.1200 7747440
23. bZIP proteins of human gammaherpesviruses. Sinclair AJ, J Gen Virol 2003 84 1941 1949 10.1099/vir.0.19112-0 12867624 (Pubitemid 36927223)
24. Unexpected structure of Epstein-Barr virus lytic cycle activator Zta. Sinclair AJ, Trends Microbiol 2006 14 289 291 10.1016/j.tim.2006.05.003 16730442 (Pubitemid 43963362)
25. Investigation of the multimerization region of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) protein K-bZIP: the proposed leucine zipper region encodes a multimerization domain with an unusual structure. Al Mehairi S, Cerasoli E, Sinclair AJ, J Virol 2005 79 7905 7910 10.1128/JVI.79.12.7905-7910.2005 15919946 (Pubitemid 40756827)
26. Strain variation in Epstein-Barr virus immediate early genes. Packham G, Brimmell M, Cook D, Sinclair AJ, Farrell PJ, Virology 1993 192 541 550 10.1006/viro.1993.1070 8093650 (Pubitemid 23232027)
27. RAZ, an Epstein-Barr virus transdominant repressor that modulates the viral reactivation mechanism. Furnari FB, Zacny V, Quinlivan EB, Kenney S, Pagano JS, J Virol 1994 68 1827 1836 8107245 (Pubitemid 24065753)
28. Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Zhang Q, Gutsch D, Kenney S, Mol Cell Biol 1994 14 1929 1938 8114724 (Pubitemid 24074588)
29. The Epstein-Barr virus immediate-early protein BZLF1 regulates p53 function through multiple mechanisms. Mauser A, Saito S, Appella E, Anderson CW, Seaman WT, Kenney S, J Virol 2002 76 12503 12512 10.1128/JVI.76.24.12503-12512. 2002 12438576 (Pubitemid 35386936)
30. Stable expression of Epstein-Barr virus BZLF-1-encoded ZEBRA protein activates p53-dependent transcription in human Jurkat T-lymphoblastoid cells. Dreyfus DH, Nagasawa M, Kelleher CA, Gelfand EW, Blood 2000 96 625 634 10887127 (Pubitemid 30463384)
31. Functional interaction between Epstein-Barr virus replication protein Zta and host DNA damage response protein 53BP1. Bailey SG, Verrall E, Schelcher C, Rhie A, Doherty AJ, Sinclair AJ, J Virol 2009 83 11116 11122 10.1128/JVI.00512-09 19656881
32. Biophysical analysis of natural variants of the multimerization region of Epstein-Barr virus lytic-switch protein BZLF1. Hicks MR, Balesaria S, Medina-Palazon C, Pandya MJ, Woolfson DN, Sinclair AJ, J Virol 2001 75 5381 5384 10.1128/JVI.75.11.5381-5384.2001 11333921 (Pubitemid 32448562)
33. A model for the interaction between NF-kappa-B and ASPP2 suggests an I-kappa-B-like binding mechanism. Benyamini H, Leonov H, Rotem S, Katz C, Arkin IT, Friedler A, Proteins 2009 77 602 611 10.1002/prot.22473 19507243
34. Insight into the structural basis of pro- and antiapoptotic p53 modulation by ASPP proteins. Ahn J, Byeon IJ, Byeon CH, Gronenborn AM, J Biol Chem 2009 284 13812 13822 10.1074/jbc.M808821200 19246451
35. Identification of constitutive phosphorylation sites on the Epstein-Barr virus ZEBRA protein. El-Guindy AS, Paek SY, Countryman J, Miller G, J Biol Chem 2006 281 3085 3095 16321978 (Pubitemid 43845918)
36. EBV the prototypical human tumor virus - just how bad is it? Thorley-Lawson DA, J Allergy Clin Immunol 2005 116 251 261 quiz 262 10.1016/j.jaci.2005.05.038 16083776 (Pubitemid 41096526)
37. Nucleoprotein structure of immediate-early promoters Zp and Rp and of oriLyt of latent Epstein-Barr virus genomes. Niller HH, Salamon D, Uhlig J, Ranf S, Granz M, Schwarzmann F, Wolf H, Minarovits J, J Virol 2002 76 4113 4118 10.1128/JVI.76.8.4113-4118.2002 11907252 (Pubitemid 34250577)
38. Epigenetic dysregulation of the host cell genome in Epstein-Barr virus-associated neoplasia. Niller HH, Wolf H, Minarovits J, Semin Cancer Biol 2009 19 158 164 10.1016/j.semcancer.2009.02.012 19429479
39. Epigenetic regulation of latent Epstein-Barr virus promoters. Takacs M, Banati F, Koroknai A, Segesdi J, Salamon D, Wolf H, Niller HH, Minarovits J, Biochim Biophys Acta 2010 1799 228 235 19853674
40. Activation and targeting of immunoglobulin switch recombination by activities induced by EBV infection. Li MJ, Maizels N, J Immunol 1999 163 6659 6664 10586061
41. Analysis of Epstein-Barr virus reservoirs in paired blood and breast cancer primary biopsy specimens by real time PCR. Perkins RS, Sahm K, Marando C, Dickson-Witmer D, Pahnke GR, Mitchell M, Petrelli NJ, Berkowitz IM, Soteropoulos P, Aris VM, et al. Breast Cancer Res 2006 8 70 10.1186/bcr1627 17163997 (Pubitemid 350201711)
42. Breast cancer risk and "delayed" primary Epstein-Barr virus infection. Yasui Y, Potter JD, Stanford JL, Rossing MA, Winget MD, Bronner M, Daling J, Cancer Epidemiol Biomarkers Prev 2001 10 9 16 11205495 (Pubitemid 32106039)
43. Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol). Arbach H, Viglasky V, Lefeu F, Guinebretiere JM, Ramirez V, Bride N, Boualaga N, Bauchet T, Peyrat JP, Mathieu MC, et al. J Virol 2006 80 845 853 10.1128/JVI.80.2.845-853.2006 16378986 (Pubitemid 43062896)
44. Lytic viral replication as a contributor to the detection of Epstein-Barr virus in breast cancer. Huang J, Chen H, Hutt-Fletcher L, Ambinder RF, Hayward SD, J Virol 2003 77 13267 13274 10.1128/JVI.77.24.13267-13274.2003 14645583 (Pubitemid 37494322)
45. Association of Epstein Barr virus infection (EBV) with breast cancer in rural Indian women. Joshi D, Quadri M, Gangane N, Joshi R, PLoS One 2009 4 8180 10.1371/journal.pone.0008180 19997605
46. Epstein-Barr virus in epithelial cell tumors: a breast cancer study. Labrecque LG, Barnes DM, Fentiman IS, Griffin BE, Cancer Res 1995 55 39 45 7805038
47. Epstein-Barr virus gene expression in human breast cancer: protagonist or passenger? Xue SA, Lampert IA, Haldane JS, Bridger JE, Griffin BE, Br J Cancer 2003 89 113 119 10.1038/sj.bjc.6601027 12838311 (Pubitemid 36897946)
48. Mutations of NFKBIA, encoding IkappaB alpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases. Lake A, Shield LA, Cordano P, Chui DT, Osborne J, Crae S, Wilson KS, Tosi S, Knight SJ, Gesk S, et al. Int J Cancer 2009 125 1334 1342 10.1002/ijc.24502 19507254
49. Germline mutations and polymorphisms in the NFKBIA gene in Hodgkin lymphoma. Osborne J, Lake A, Alexander FE, Taylor GM, Jarrett RF, Int J Cancer 2005 116 646 651 10.1002/ijc.21036 15858823 (Pubitemid 41099203)
50. The first 30 years of p53: growing ever more complex. Levine AJ, Oren M, Nat Rev Cancer 2009 9 749 758 10.1038/nrc2723 19776744
51. NFkappaB and p53: A life and death affair. Oren M, Cooks T, Cell Cycle 2010 9
52. Mutant p53 gain-of-function in cancer. Oren M, Rotter V, Cold Spring Harb Perspect Biol 2010 2 001107 10.1101/cshperspect.a001107 20182618
53. Virus target cell conditioning model to explain some epidemiologic characteristics of childhood leukemias and lymphomas. zur Hausen H, de Villiers EM, Int J Cancer 2005 115 1 5 10.1002/ijc.20905 15688417 (Pubitemid 40559663)
54. HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma. Hjalgrim H, Rostgaard K, Johnson PC, Lake A, Shield L, Little AM, Ekstrom-Smedby K, Adami HO, Glimelius B, Hamilton-Dutoit S, et al. Proc Natl Acad Sci USA 2010 107 6400 6405 10.1073/pnas.0915054107 20308568
55. Activation of maternal Epstein-Barr virus infection and risk of acute leukemia in the offspring. Tedeschi R, Bloigu A, Ogmundsdottir HM, Marus A, Dillner J, dePaoli P, Gudnadottir M, Koskela P, Pukkala E, Lehtinen T, Lehtinen M, Am J Epidemiol 2007 165 134 137 17005627 (Pubitemid 46096374)
56. Serum antibody response to lytic and latent Epstein-Barr virus antigens in undifferentiated nasopharyngeal carcinoma patients from an area of nonendemicity. Tedeschi R, Pin E, Martorelli D, Bidoli E, Marus A, Pratesi C, Bortolin MT, Zanussi S, Vaccher E, Dolcetti R, De Paoli P, Clin Vaccine Immunol 2007 14 435 441 10.1128/CVI.00466-06 17329446 (Pubitemid 46732555)
57. The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. Hadinoto V, Shapiro M, Sun CC, Thorley-Lawson DA, PLoS Pathog 2009 5 1000496 10.1371/journal.ppat.1000496 19578433